Form S-3 PERNIX THERAPEUTICS HOLD
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Pernix Therapeutics (PTX) Posts Q3 Loss of 2c/Share
November 10, 2014 8:28 AM ESTPernix Therapeutics (NASDAQ: PTX) reported Q3 EPS of ($0.02), $0.02 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $31.5 million versus the consensus estimate of $28.1 million.
Pernix Therapeutics reaffirmed FY2014 guidance.
For earnings history and earnings-related data on Pernix Therapeutics (PTX) click here.
... MorePernix Therapeutics (PTX) Files $300M Mixed Shelf
November 10, 2014 8:27 AM ESTPernix Therapeutics (NASDAQ: PTX) filed with the U.S. SEC to sell up to $300 million of mixed securities.
... More